Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors

NCT06209580 is registered in ClinicalTrials.gov with Multitude Therapeutics Inc. as lead sponsor.

NCT NCT06209580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06209580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors
Lead sponsor
Multitude Therapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 31, 2024
Completion date
December 31, 2026
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, malignant melanoma